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ABSTRACT 
!
p53 is a central player in the cellular response to stress, allowing cells to cope in the presence of 
diverse stress signals including DNA damage and oncogene activation. In response to stress, p53 
acts as a transcription factor to regulate the expression of protein-coding and non-coding RNA 
genes that collectively result in cell cycle arrest, senescence or apoptosis. One such p53-
regulated gene encodes the Pirh2 protein, an E3 ubiquitin ligase known to ubiquitinate many 
substrates including p53, p27/Kip1 cell cycle inhibitor and DNA polymerase η. The objective of 
this project was to validate a putative interaction between Pirh2 and Protein Kinase Cδ and 
determine if the latter was a substrate for Pirh2-mediated ubiquitination. While data suggest that 
Pirh2 protein expression negatively correlates with PKCδ protein levels, it could not be 
confirmed that Pirh2 mediates ubiquitin-dependent degradation of PKCδ protein.
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Normal cellular function relies on both intra- and inter-cellular communication, the integration of 
such signals and the mounting of appropriate cellular responses such that cells grow, proliferate, 
develop or die. Central to such cellular functions are thousands of proteins and enzymes that 
relay intracellular signals and mediate intracellular trafficking, cellular motility and metabolism. 
Cells must thus regulate protein function such that proteins are only made and active when 
needed, in response to a specific signal or a cellular event. Different cellular mechanisms are 
elicited to modulate protein function including regulation at the transcriptional, translational and, 
more commonly, the post-translational levels. One such mechanism is through control of target 
protein intracellular levels by covalent conjugation of the ubiquitin (Ub) protein moiety to 
specific lysine (Lys) residues on substrate proteins, in a process termed ubiquitination, which 
mostly results in protein degradation by the 26S proteasome (Glickman and Ciechanover, 2002). 
In addition to targeting proteins for proteolysis, ubiquitination modulates countless cellular 
processes including cell cycle progression, protein trafficking, transcription factor activity and 
cellular apoptosis (Deshaies and Joazeiro, 2009). The objective of this thesis was to investigate a 
putative interaction between the p53-induced protein with a RING-H2 domain (Pirh2) and the 
protein kinase Cδ (PKCδ) and elucidate its significance. Pirh2 functions as an E3 ubiquitin ligase 
for many cellular substrates including p53 and p27. The first part of the introduction will focus 
on the physiological process of ubiquitination.  
!
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UBIQUITINATION 
!
Ubiquitin is a 76 amino acid polypeptide that can act as a protein tag through conjugation of its 
C-terminus to an amino group within a protein substrate (Pickart, 2001). The C-terminal glycine 
residue (Gly76) of ubiquitin is usually conjugated to the ε-NH2 group of a substrate lysine or, less 
frequently, to the free α-NH2 group of specific proteins such as the cell cycle inhibitor p21 
protein (Bloom et al., 2003; Reinstein et al., 2000). The attachment of a polyubiquitin chain, 
consisting of at least four ubiquitin moieties, to a protein targets it for destruction through the 
26S proteasome while conjugation of ubiquitin monomers and chains through specific linkages 
may modulate protein function by influencing protein-protein interactions, subcellular location 
or activity (Passmore and Barford, 2004). The attachment of a ubiquitin polypeptide to a protein 
can take on multiple forms, and it is the topology of the attached ubiquitin tag that mediates 
protein fate: (a) monoubiquitination, the conjugation of a ubiquitin monomer to a single lysine 
residue; (b) multiubiquitination, the attachment of multiple ubiquitin monomers to different 
lysines; and (c) polyubiquitination, the attachment of a ubiquitin polymer to one or more lysine 
residues within a protein substrate (Henry et al., 2003; Haglund et al., 2003; Bloom et al., 2003). 
The formation of a ubiquitin polymer relies on conjugation of ubiquitin monomers to Lys 
residues within an already appended ubiquitin moiety, and indeed, ubiquitin has seven lysines 
that can participate in polymerization (Lys6, 11, 27, 29, 33, 48 and 63) (Fang and Weissman, 
2004; Glickman and Ciechanover, 2002). The Lys48-linked polymer targets tagged proteins to the 
26S proteasome for degradation, while the Lys63-linked polymer may signal non-proteolytic 
functions such as changes in subcellular localization and protein activation (Schnell and Hicke, 
!3
2003; Ikeda and Dikic, 2008). Ubiquitin polymers through Lys6, Lys11 and Lys29 have also been 
reported, and while the former resembles the Lys63-linked polymer in function, the latter two 
polymers may target proteins to the proteasome (Passmore and Barford, 2004; Schnell and 
Hicke, 2003). In addition to ubiquitin, a family of ubiqutin-like proteins are also found including 
the Small Ubiquitin-related Modifier 1 (SUMO-1) and Neural precursor cell Expressed, 
Developmentally Down-regulated protein 8 (Nedd8) proteins, and these proteins are thought to 
modulate protein function both in concert and independently of ubiquitin through conjugation to 
specific substrates (Ciechanover, 1998).  
 The conjugation of ubiquitin is thought to proceed through a complex and highly 
regulated mechanism involving the sequential actions of three classes of enzymes: the E1 
ubiquitin-activating enzyme, the E2 ubiquitin-conjugating enzyme and the E3 ubiquitin-ligating 
enzyme (Pickart, 2001). Mechanistic details of ubiquitin conjugation are discussed next.   
!
The ubiquitination mechanism 
The ubiquitination reaction starts with the E1 ubiquitin-activating enzyme, which sequentially 
binds Magnesium (Mg2+)-coordinated ATP followed by ubiquitin (Pickart, 2001). Binding of 
ATP greatly increases the affinity of the E1 enzyme for ubiquitin (Haas and Rose, 1982; Hershko 
et al., 1983). Residues within the E1 active site position the ATP molecule such that the C-
terminal Gly76 residue can attack the ATP α-phosphate and activate ubiquitin, resulting in the 
formation of a ubiquitin adenylate intermediate (Walden et al., 2003). This intermediate then 
serves as a ubiquitin donor to an E1 active site cysteine (Cys; C) residue which, in a similar 
nucleophilic mechanism, attacks the ubiquitin adenylate, resulting in the formation of an E1-Ub 
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thioester intermediate (Pickart, 2001). The E1 ubiquitin-activating enzyme is fully activated 
when it is bound to active ubiquitin both covalently as a ubiquitin thioester within its active site 
and non-covalently as a ubiquitin adenylate intermediate (Pickart, 2001; Passmore and Barford, 
2004). The E1-Ub thioester intermediate next serves as a ubiquitin donor to an E2 ubiquitin-
conjugating enzyme (Glickman and Ciechanover, 2002).  
 The organization of the ubiquitin enzyme cascade is hierarchical with only two E1 
enzymes providing activated ubiquitin to about 40 different E2 ubiquitin-conjugating enzymes 
(Deshaies and Joazeiro, 2009). All E2 enzymes share a core globular domain of about 150 amino 
acids, and structural studies revealed that a Cys residue sits in a shallow groove in the E2 active 
site, ready to attack the E1-Ub thioester intermediate, resulting in the formation of an E2-Ub 
thioester intermediate and regenerating the E1 active site cysteine (Pickart, 2001; Glickman and 
Ciechanover, 2002). The E2 enzyme preferentially binds Ub-loaded E1 enzymes over either free 
E1 or ubiquitin molecules, and it is the E1 enzyme that brings ubiquitin and the E2 enzyme 
together to mediate ubiquitin transfer from itself to the E2 active site in a transesterification 
reaction (Pickart, 2001). The E2-Ub thioester intermediate acts as the ubiquitin donor for the 
third step of the reaction catalyzed by the E3 ubiquitin-ligating enzymes (Glickman and 
Ciechanover, 2002). 
 The E3 ubiquitin ligase family of enzymes consists of several hundred to a thousand 
members and are key enzymes that impart substrate specificity to the ubiquitination reaction 
(Pickart, 2001; Glickman and Ciechanover, 2002). E3 enzymes are thought to mediate substrate 
specificity through specific protein-binding domains that participate in recruitment of the 
substrate, while other domains are responsible for the recruitment of the Ub-loaded E2 enzyme 
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(Pickart and Eddins, 2004; Glickman and Ciechanover, 2002; Deshaies and Joazeiro, 2009). E2 
enzymes dock on a shallow hydrophobic groove within the E3 ligase structure after which the E3 
enzyme mediates the transfer of an activated ubiquitin moiety from the E2 enzyme to an amino 
group within the substrate protein, resulting in a ubiquitin-conjugated protein and regenerating 
the catalytic Cys residue in the E2 active site (Hershko et al., 1983; Pickart, 2001; Deshaies and 
Joazeiro, 2009). This final ubiquitin transfer reaction results in the conjugation of a ubiquitin 
monomer to a protein, and the generation of oligo- and poly-ubiquitinated substrates involves 
repetition of the aforementioned mechanism (Pickart, 2001). Figure 1 illustrates the 
ubiquitination mechanism. The E3 ligase family of proteins are subdivided into two families 
based on the structure of their catalytic domain: the (a) homologous to E6-Associated Protein 
(E6-AP) C-terminus domain (HECT) domain E3 subfamily and the (b) Really Interesting New 
Gene (RING) domain E3 subfamily (Passmore and Barford, 2004; Pickart, 2001).   
!
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FIGURE 1: THE UBIQUITINATION MECHANISM. Free ubiquitin (Ub) is conjugated 
through its C-terminus to a Cys residue in the E1 active site in an ATP-dependent reaction. Ub-
loaded E1 then transfers its conjugated ubiquitin to an active site Cys residue in the E2 enzyme, 
regenerating the E1 active site and resulting in the formation of Ub-loaded E2 enzyme. This 
enzyme can interact with members of the HECT family of E3 ligases, which form an E3-Ub thiol 
intermediate prior to attachment of ubiquitin to the substrate, or with members of the RING 
family of E3 ligases, which act as molecular scaffolds to mediate direct transfer of ubiquitin from 
the E2 to the substrate. Reproduced from Weissman (2001).  
!
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The E3 ubiquitin ligase family 
Members of the HECT and RING subfamilies of E3 ligases both catalyze the final step of the 
ubiquitination reaction, the conjugation of the ubiquitin moiety to a target substrate, albeit by 
different mechanisms. While HECT domain E3 ligases participate catalytically in the 
ubiquitination reaction by acting as the final ubiquitin thioester donor, RING domain ligases are 
thought to act as molecular scaffolds to allow the direct transfer of ubiquitin from the E2 enzyme 
to the substrate, as discussed below. 
!
(a) HECT domain E3 ligases  
This family of E3 ligases consists of members who share high homology to the C-terminus 
domain of the founding member, the E6-AP E3 ligase (Fang and Weissman, 2004). HECT E3 
ligases are modular proteins: a highly conserved HECT domain of about 350 amino acids lies at 
the C-terminus of the ligase, while a substrate-interacting module lies at the N-terminus (Pickart, 
2001). A catalytic Cys lies about 35 amino acids upstream of the C-terminus domain, and this 
Cys is thought to attack the E2-Ub thioester intermediate, in a transthiolation reaction, to result 
in the formation of an E3-Ub thioester intermediate and regeneration of the catalytic Cys in the 
E2 active site (Pickart, 2001; Scheffner et al., 1995; Fang and Weissman, 2004; Glickman and 
Ciechanover, 2002; Figure 1). A protein substrate, bound by the N-terminus substrate binding 
domain, has it amino group poised for attack on the Ub-loaded E3 intermediate such that an 
isopeptide bond forms between the C-terminal Gly residue of ubiquitin and the ε-amino group of 
a substrate Lys, or less commonly, an α-amino group of a protein, which results in a ubiquitin-
conjugated protein (Glickman and Ciechanover, 2002).  
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(b) RING domain E3 ligases 
This family of E3 ligases consists of an estimated 600 members, all of whom share a conserved 
Cys-rich motif termed the RING domain (Deshaies and Joazeiro, 2009). The RING domain is a 
globular Zinc (Zn2+) binding motif consisting of the base sequence (Cys-X2-Cys-X(9-39)-Cys-
X(1-3)-His-X(2-3)-Cys-X2-Cys-X(4-48)-Cys-X2-Cys, where His is histidine (H) and X is any amino 
acid), which binds two Zn2+ ions in a cross-brace structure (Deshaies and Joazeiro, 2009; Pickart, 
2001). Much like HECT domain E3 ligases, RING domain E3 ligases are modular proteins that 
have a substrate-binding site, which binds target proteins, and a distinct RING domain that is 
thought to mediate structural, non-catalytic functions through recruitment and binding of the Ub-
conjugated E2 enzyme (Pickart, 2001). Unlike HECT domain ligases, RING E3 ubiquitin ligases 
do not participate in the catalytic mechanism directly, rather, they act as molecular scaffolds that 
facilitate direct substrate ubiquitination by Ub-conjugated E2 enzymes through proximity, by 
effectively increasing the local concentration of Lys residues available to attack the E2-
conjugated ubiquitin, and through E2 and E3 conformational changes that are induced upon E2-
E3 binding (Passmore and Barford, 2004; Deshaies and Joazeiro, 2009; Figure 1). Based on 
protein structural analysis, members of this family can be further subdivided into two classes: (i) 
single subunit RING E3 ubiquitin ligases, such as the p53 ubiquitin ligase Mdm2, which have 
both the RING domain and substrate binding motifs as part of the same polypeptide, and (ii) 
multi-subunit RING E3 ubiquitin ligases, such as the Skp-Cullin-F-box (SCF) E3 ligases, where 
the RING domain and substrate binding motifs are provided by distinct proteins and coordinated 
by adaptor and scaffold proteins (Deshaies and Joazeiro, 2009). Non-catalytic proteins with 
RING domain structures have been identified and are thought to function as modulators of the 
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E3 RING ligase enzymes through RING domain dimerization (Fang and Weissman, 2004; Gu et 
al., 2002; Deshaies and Joazeiro, 2009). 
 A third, less defined class of RING E3 ligases is defined by proteins with U-box domains, 
which is believed to be a RING domain variant, that also mediates ubiquitination by acting as a 
molecular scaffold (Fang and Weissman, 2004; Figure 2). The U-box domain lacks Zn2+ 
coordinating residues, relying instead on conserved intra-domain electrostatic interactions and 
hydrogen bonds to maintain its structural fold and it is as of yet only present in a handful of 
proteins but further characterization of E3 ligases may reveal additional family members (Pickart 
and Eddins, 2004).  
!
Regulation of ubiquitination 
As of any complex system that modulates protein function, regulation of ubiquitination is vital 
for proper cellular function and a number of mechanisms exist that serve to positively and 
negatively affect substrate ubiquitination, which are next discussed.  
(I) Degradation signal: Amino acid sequences such as the destruction box, a sequence of 9 
amino acid residues with invariant arginine and leucine at positions 1 and 4, respectively, and 
protein structural motifs, such as the hydrophobic face of an amphipathic helix, have both been 
identified as signals that promote ubiquitination and degradation (Ciechanover, 1998; Pickart, 
2001). However, the frequency with which these signals are found in protein substrates is quite 
low, and thus the selection of a specific Lys residue within a substrate is thought to be non-
specific, although Deshaies and Joazeiro (2009) suggest that a basic microenvironment around 
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specific Lys residues may target them for deprotonation, thus functionally acting as degradation 
signals. 
(II) Formation and topology of polyubiquitin chains: Certain E3 ligases can only catalyze 
monoubiquitination reactions, and thus another E2-E3 ligase pair is needed to elongate the 
ubiquitin chain and form polymers, which may be referred to as an E4 polyubiquitin ligase or E4 
ubiquitin chain assembly factor (Grossman et al., 2003; Shi et al., 2009). As an example, the p53 
tumor suppressor is multi-ubiquitinated by the Mdm2 E3 ligase but is subsequently 
polyubiquitinated by the E3 ubiquitin ligase activity of another enzyme, p300/CBP (Lai et al., 
2001; Grossman et al., 2003; Shi et al., 2009). In addition, a number of ubiquitin-binding protein 
motifs have been identified in different proteins including the Ubiquitin-Associated Domain and 
Ubiquitin-Interacting Motif, and these may function as E4 ubiquitin chain assembly factors to 
enhance polyubiquitination, may stabilize polyubiquitin chains and prevent their de-
ubiquitination, or may serve to cap the growing ubiquitin chain after the addition of a specific 
number of residues to favor mono- or oligo-ubiquitination (Koegl et al., 1999; Flick et al., 2006; 
Fang and Weissman, 2004). The specific linkage between the ubiquitin monomers within a 
polyubiquitin chain is determined by both the E2 and E3 enzymes, and it is thought that each of 
these enzymes may non-covalently bind ubiquitin monomers and orient them in such a way that 
only a specific Lys residue is poised for attack (Deshaies and Joazeiro, 2009; Passmore and 
Barford, 2004).   
(III) Protein stability and proofreading: Polyubiquitinated proteins consisting of 4 or more 
ubiquitin moieties are targeted for destruction by the 26S proteasome (Ciechanover, 1998). The 
26S proteasome is a cellular organelle that performs controlled, ATP-dependent proteolysis of 
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proteins. It is composed of a barrel-shaped 20S core particle, shaped by 4 stacked rings in the 
order αββα, where the 2 β rings make up the proteolytic core which harbor trypsin-, 
chymotrypsin- and peptidyl-hydrolase-like protease activities (Herrmann et al., 2007). The α 
rings serve to stabilize the proteolytic sites, to regulate entry into the catalytic core and to bind, 
on both ends of the barrel, to two 19S regulatory particles (Glickman and Ciechanover, 2002). 
The regulatory 19S particle serves many functions: it associates with ubiquitin-binding proteins 
that help recognize and recruit polyubiquitinated substrates to the proteasome; it contains a 
number of ATPase subunits that participate in the ATP-dependent unfolding and translocation of 
protein substrates; and it stabilizes and gates the entry of proteins into the proteolytic core 
(Glickman and Ciechanover, 2002). Finally, associated with the proteasome are de-ubiquitinating 
enzymes that catalyze the recycling of ubiquitin monomers, both from polyubiquitinated proteins 
and peptides released from the proteasome, and that function in the editing and proofreading of 
ubiquitin-conjugated proteins to ensure that only proteins meant for destruction are targeted to 
the proteasome (Fang and Weissman, 2004; Ciechanover, 1998).   
(IV) Post-translational modifications: Post-translational modifications of both E3 ligases and 
substrate proteins are involved in the regulation of ubiquitination and include phosphorylation of 
the substrate, as in the case of IκBα, which must be phosphorylated at both Serine (Ser) 32 and 
Ser36 residues prior to ubiquitination, and of the E3 ubiquitin ligase, as in the case of Mdm2, 
which is phosphorylated by Protein Kinase B which results in enhanced interaction with its 
substrate (Chen et al., 1995; Ogawara et al., 2002). Additionally, sumoylation and neddylation of 
E3 ligases have been reported to enhance the enzymatic activity of both the Mdm2 and SCF 
protein complex, respectively, while sumoylation of both Mdm2 and IκBα are thought to 
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compete with ubiquitin for binding to specific Lys residues and thus interferes with their 
ubiquitination (Buschmann et al., 2000; Duda et al., 2008; Desterro et al., 1998). Ubiquitination 
itself targets many E3 ligases for degradation, while oligomerization of RING and SCF E3 
ligases have been reported to be important for their enzymatic activity (Deshaies and Joazeiro, 
2009). Finally, other post-translational modifications may influence ubiquitination, such as the 
oxidation of the Hypoxia Inducible Factor-1α transcription factor which targets it for 
degradation, and the acetylation of the p53 transcription factor at various Lys residues which 
competes with its ubiquitination (Jaakkola et al., 2001; Weissman, 2001).   
 Ubiquitination, being a complex but essential cellular mechanism, is involved in a 
number of pathologies and malignancies where E3 ligases have been reported to be mutated or 
aberrantly expressed. The E3 ubiquitin ligases, a family of enzymes that is reported to outnumber 
kinases, thus present themselves as potential disease biomarkers and highly valuable drug 
targets, due to their physiological and clinical significance.  
 This thesis project was aimed at understanding the physiological role of the p53-induced 
RING-H2-containing E3 ubiquitin ligase Pirh2. 
!
THE Pirh2 E3 UBIQUITIN LIGASE  
!
The PIRH2 gene was first identified as a p53 target gene by Leng et al. (2003) through a 
differential display assay using the mouse erythroleukemia cell line DP16.1/p53ts, which 
encodes a temperature-sensitive p53 that assumes a wild-type conformation at 32℃ and a mutant 
conformation at 37℃. The p53 tumour suppressor protein is a central player in the cellular 
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response to stress. In response to diverse stress signals including DNA damage, nutrient 
deprivation and oncogene activation, p53 protein becomes activated and functions as a sequence-
specific DNA-binding transcription factor to regulate the expression of both protein-coding and 
non-coding RNA genes that collectively result in cell cycle arrest, senescence or apoptosis.!Due 
to the integral role of p53 in the cellular stress response, p53 protein expression is lost or its 
function otherwise impaired in almost all cancers (Vousden, 2006). 
 Characterization of the PIRH2 gene product revealed that it encodes a 261 amino acid 
protein with a central RING-H2 domain, named the p53-induced protein with a RING-H2 
domain, and that the protein functions as a single subunit, E3 ubiquitin ligase that targets both 
itself and p53 for ubiquitination. Pirh2 was shown to regulate the steady state levels of p53 
protein by interacting with and ubiquitinating p53 both in vivo and in vitro, thus participating in 
an auto-regulatory feedback loop, much like Mdm2 (Leng et al., 2003). Subsequently, Pirh2 was 
found to preferentially regulate protein levels of active p53 protein, targeting it for 
polyubiquitination and proteasome-mediated degradation, specifically under cellular stress 
conditions (Sheng et al., 2008; Hakem et al., 2011). However, the functional significance of 
having yet another E3 ligase target the p53 protein for degradation is still unclear, and this high 
level of functional redundancy, coupled with the ability of Pirh2 to induce ubiquitination in the 
absence of p53 protein both in vitro and in vivo, led many to believe that Pirh2 mediates the 
degradation of additional cellular substrates (Leng et al., 2003). Indeed, a number of additional 
substrates have been identified including the p27/Kip1 cyclin-dependent kinase inhibitor, c-myc, 
checkpoint kinase 2 (Chk2) and DNA Polymerase η (Hattori et al., 2007; Hakem et al., 2011; 
Bohgaki et al., 2013; Jung et al., 2011). Pirh2 protein levels are regulated both at the 
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transcriptional level, through p53-induced gene expression, and post-translationally through self-
ubiquitination, which destabilizes the protein and tags it for degradation, and through protein-
protein interactions with the Tat-interactive protein of 60 kDa (Tip60), which functions to 
stabilize Pirh2 protein in the cell (Leng et al., 2003; Sheng et al., 2008; Logan et al., 2004). 
Finally, Pirh2 can be phosphorylated by two distinct protein kinases: the Calmodulin-dependent 
kinase II (CaMK II), which phosphorylates the threonine (Thr)-154 and Ser-155 residues, and the 
Cyclin-Dependent Kinase 9 (Cdk9), which phosphorylates the Ser-211 and Thr-217 residues 
(Duan et al., 2007; Bagashev et al., 2013). Both phosphorylation events abrogate the E3 ligase 
activity of Pirh2 towards p53 and shorten Pirh2 half-life by enhancing self-ubiquitination (Duan 
et al., 2007; Bagashev et al., 2013).   
  Previous research in our lab identified a putative interaction of Pirh2 protein with Protein 
Kinase Cδ (PKCδ). Purified Glutathione-S-Transferase (GST) or GST-hPirh2 fusion proteins 
were used as bait to fish for interacting partners using Pirh2 null (Pirh2-/-) immortalized kidney 
fibroblast lysates in a GST-pulldown assay, and bound proteins were resolved by Sodium 
Dodecyl Sulphate-Poly-Acrylamide Gel Electrophoresis (SDS-PAGE) (Tai, 2009). Protein bands 
that were exclusive to the GST-hPirh2 lane were excised and analyzed by Matrix-Assisted Laser 
Desorption Ionization (MALDI) Mass Spectrometry (MS)/MS, which identified a fragment of 
the Protein Kinase C δ N-terminus as an interacting partner of Pirh2 (Tai, 2009). 
!
!
!
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THE PROTEIN KINASE C SUPERFAMILY 
!
Protein phosphorylation is a key protein modulation event that is mediated by over 500 distinct 
kinases within the cell. Members of the Protein Kinase C (PKC) family were first identified 
almost 30 years ago and are thought to participate in diverse cellular responses including cellular 
proliferation, apoptosis and immunity (Mackay and Twelves, 2007; Griner and Kazanietz, 2007).    
!
The PKC family 
The PKC family of enzymes consists of ten serine/threonine kinases that belong to the AGC 
family of protein kinases (Mackay and Twelves, 2007; Steinberg, 2008). PKC was first identified 
as an enzyme that requires both calcium (Ca2+) and diacylglycerol (DAG), a membrane-bound 
second messenger product of phosphatidylinositol (PI) hydrolysis, for its activity, however, 
subsequent studies revealed that different isozymes are activated by different combinations of 
cofactors (Takai et al., 1979; Breitkreutz et al., 2007). The isozymes are subdivided into three 
subfamilies based on structural differences and cofactor requirements: classical PKCs (cPKCs: 
PKCα, the alternatively spliced PKCβ isoforms PKCβI and PKCβII, and PKCɣ isozymes), which 
require both Ca2+ and DAG binding for activation; novel PKCs (nPKCs: PKCδ, PKCθ, PKCε 
and PKCη isozymes), which require DAG binding for activation; and atypical PKCs (aPKCs: 
PKCζ and PKCλ/Ɩ), which do not require either of Ca2+ or DAG binding for activation, relying 
on protein-protein interactions instead (Griner and Kazanietz, 2007; Newton, 1995; Steinberg, 
2008; Mackay and Twelves, 2007). All family members are activated by binding to 
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phosphatidylserine, an anionic phospholipid restricted to the cytoplasmic side of the plasma 
membrane (Steinberg, 2008).  
!
Structural properties of PKC enzymes 
PKC enzymes are modular enzymes that consist of an N-terminal regulatory domain and a C-
terminal catalytic domain separated by a hinge region (Steinberg, 2008). Structural features of 
PKC enzymes are defined by four distinct protein domains: two membrane-targeting domains, 
the lipid-binding C1 domain and the phospholipid- and Ca2+-binding C2 domain, and the highly 
conserved ATP-binding C3 and substrate-binding C4 domains, which together make up the 
kinase domain (Mellor and Parker, 1998; Steinberg, 2008; Figure 2). Conserved amongst all 
three PKC subfamilies is an N-terminal pseudosubstrate domain that closely resembles PKC 
substrates which maintains the enzyme in a closed, inactive conformation until an appropriate 
signal is received (Newton, 1995; Mellor and Parker, 1998). A brief explanation of the PKC 
functional domains follows.  
!
!
!
!
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FIGURE 2: DOMAIN STRUCTURES OF THE PKC FAMILY MEMBERS. Representative 
structures from each PKC subfamily are illustrated. Regulatory and kinase domains and their 
constituent motifs are shown. The C1 domain of cPKCs and nPKCs is made up of two tandem 
motifs designated C1A and C1B, while only a single C1 motif is found in aPKcs. The 
pseudosubstrate domain (PS) is shown in green, and a unique Phox and Bem 1 (PB1) protein 
domain, implicated in mediating protein-protein interactions, is found in aPKCs. Reproduced 
from Steinberg (2008). 
!
(a) C1 domain: The C1 domain serves to anchor cPKCs and nPKCs into the plasma membrane 
by mediating interactions of PKCs with both DAG and anionic phospholipids such as 
phosphatidylserine (Newton, 1995; Steinberg, 2008). The C1 domain consists of two tandem 
cysteine-rich Zn2+ binding motifs, termed C1A and C1B (Mellor and Parker, 1998). The C1A/B 
motifs both adopt similar tertiary structures in which the upper third of each motif is a largely 
hydrophobic surface that binds DAG, the middle third is an exposed basic surface that binds 
anionic phospholipids, and the bottom third is made up of the two Zn2+-binding domains that 
maintain the C1 fold (Steinberg, 2008). DAG binding to the C1A/B motifs caps a hydrophilic 
groove within a largely hydrophobic surface, thus providing a contiguous hydrophobic surface 
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that serves to increase membrane affinity of PKCs (Newton, 1995; Steinberg, 2008). A single C1 
motif is fully capable of anchoring PKCs into the plasma membrane, and the two C1 motifs are 
thought to be non-equivalent, binding DAG with differing affinities in different PKC isozymes 
(Mellor and Parker, 1998; Steinberg, 2008). The single C1 domain in aPKCs can still recognize 
anionic phospholipids that help localize it to the membrane, however, this motif has different 
structural properties that render it unable to bind DAG, and is thought to mediate nuclear 
localization of aPKCs by housing a nuclear localization signal (Steinberg, 2008). Finally, the 
C1A domain mediates the interaction of PKC isozymes with the RING-finger protein that 
interacts with C kinase (RINCK) E3 ubiquitin ligase (Chen et al., 2007). 
(b) C2 domain: The C2 domain is another membrane-targeting domain found in cPKCs, which 
binds Ca2+ ions in a highly cooperative manner at five conserved aspartate (Asp) residues within 
its structure (Newton, 1995; Steinberg, 2008). This domain binds anionic phospholipids weakly 
and transiently in the absence of Ca2+, however, upon Ca2+ binding, a conformational change is 
triggered that increases the affinity of the enzyme for the plasma membrane, allowing the 
docking of the enzyme at the membrane where it encounters DAG and becomes fully active 
(Newton, 1995). The C2-like domain of nPKCs conserves structural residues required for 
maintaining the C2 fold, but lacks the conserved Asp residues required for Ca2+ binding, and as 
such cannot be activated by Ca2+ (Mellor and Parker, 1998). The C2 domains of of the nPKCs 
PKCδ and PKCθ were characterized as phosphotyrosine binding domains, which may help 
recruit these isozymes to the plasma membrane and allow for their activation during agonist-
induced cellular signaling (Benes et al., 2005; Stahelin et al., 2012). aPKCs lack the structural 
residues required for maintaining the C2 fold and this domain is thus absent (Steinberg, 2008).   
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(c) Kinase domain (C3 and C4): The C3 and C4 domains form the nucleotide binding and 
substrate binding domains, respectively, in the PKC active site (Steinberg, 2008). These domains 
are highly conserved in the AGC family and consists of a glycine-rich ATP binding motif that 
anchors the non-transferable phosphate groups in the active site, a conserved Lys residue that 
orients the ATP molecule for catalysis through coordination of its α and β phosphate groups, and 
an activation loop that orients Mg2+ and the peptide substrate for optimal enzyme catalysis 
(Steinberg, 2008). The activation loop is the site of a crucial phosphorylation event that primes 
kinases for activation (Newton, 1995). A mutation in the aforementioned Lys residue abolishes 
enzymatic activity in cPKCs and nPKCs and is used to generate kinase-dead enzyme mutants in 
the laboratory, however, this mutation is well-tolerated in aPKCs hinting that their ATP-binding 
motifs are distinct from those in other PKCs (Steinberg, 2008; Spitaler et al., 2000).  
(d) The pseudosubstrate motif: The pseudosubstrate motif is an amino acid sequence that highly 
resembles the optimal PKC substrate sequence but where an alanine residue is found in lieu of 
phosphoacceptor amino acids such as Ser and Thr (Mellor and Parker, 1998). PKC active sites 
are constitutively occupied by the pseudosubstrate motif in inactive enzymes, however, upon 
enzyme activation, the accompanying conformational changes displace this motif from the active 
site to allow binding of specific substrates (Newton, 1995). This motif is conserved across all 
three subfamilies and is usually found N-terminal to the C1 motif (Steinberg, 2008).  
(e) The hinge region: The hinge region is a region that varies between the different PKC 
isoforms which separates the N-terminal regulatory domain from the C-terminal catalytic 
domain. In some isozymes, including PKCδ, θ, ε and ζ, this domain acts as the recognition site 
for caspase-mediated cleavage during apoptotic signaling (Steinberg, 2008).  
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(f) The V5 domain: This is another region in the PKC structure that varies between members of 
the PKC family, located at the extreme C-terminus of the protein (Figure 2). This domain is the 
site of two crucial phosphorylations that prime enzymes for activation: the turn motif and 
hydrophobic motif phosphorylations, which are thought to participate in stabilizing the 
enzymatic structure and are essential for enzymatic activity (Newton, 1995; Steinberg, 2008). It 
is at this site that the alternatively spliced PKCβI and PKCβII isozymes differ, which allows 
these isozymes to localize differently and mediate separate functions within the cell (Chalfant et 
al., 1995). A nuclear localization signal has also been identified in the V5 domain of PKCδ, 
which targets this isozyme to the nucleus during apoptosis, where it encounters its substrates and 
participates in the apoptotic response (DeVries et al., 2002).  
!
The PKC activation mechanism 
PKC structure elucidation allowed the formulation of an activation mechanism for PKC enzymes 
in response to agonist binding at the cell surface. A general mechanism for activation of cPKCs 
is explained next, and deviations from this mechanism in nPKC enzyme activation are noted. 
aPKCs are thought to be activated by protein-protein interactions mediated through their PB1 
domain (Parker and Murray-Rust, 2004).  
 PKC activation is downstream of signaling cascades that result in PI hydrolysis (Newton, 
1995). When an agonist engages a membrane-bound G-protein coupled receptor (GPCR) or a 
receptor tyrosine kinase (RTK), either of phospholipase C (PLC) β or PLCɣ, respectively, are 
recruited and activated to catalyze the hydrolysis of PI(4,5) biphosphate (PIP2) to yield inositol 
triphosphate (IP3) and DAG (Mackay and Twelves, 2007; Parker and Murray-Rust, 2004). IP3 
!21
acts as an intracellular messenger that mobilizes Ca2+ from cellular stores such as the 
endoplasmic reticulum (ER), while DAG acts as a membrane-bound second messenger that 
activates membrane-targeted PKC isozymes (Koivunen et al., 2006). As aforementioned, in the 
absence of Ca2+, cPKCs only bind the plasma membrane weakly, however, Ca2+ binding initiates 
a conformational change in the C2 domain that increases the affinity of this domain for the 
plasma membrane, bringing the C1 domain in close proximity to DAG, and allowing for full 
activation of PKCs (Steinberg, 2008). Upon DAG binding, the enzyme becomes stabilized and 
releases the pseudosubstrate motif from its active site, and is now ready to mediate the 
phosphorylation of its substrates or otherwise associate with different targeting proteins that alter 
its subcellular localization (Newton, 1995; Mackay and Twelves, 2007; Koivunen et al., 2006). 
The activation mechanism of nPKCs is similar, however, the C2-like domain of nPKCs has an 
increased affinity for the plasma membrane, and as such, binding of DAG is sufficient to activate 
nPKCs (Steinberg, 2008). The C2-like domain of certain nPKCs, being a phosphotyrosine 
binding domain, may also help recruit the novel PKCδ to the membrane upon receptor tyrosine 
kinase activation, where it can encounter DAG and become fully activated (Benes et al., 2005; 
Stahelin et al., 2012). The activation mechanism of PKC is illustrated in Figure 3. 
!
!
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FIGURE 3: ACTIVATION OF PROTEIN KINASE C.  Agonist binding to either of G-protein 
coupled receptors (GPCR) or receptor tyrosine kinases (RTK) initiates a signaling cascade that 
leads to phosphatidylinositol hydrolysis and generation of the DAG second messengers, which 
serves to localize PKC enzymes to the membrane and results in their activation. Reproduced 
from Koivunen et al. (2006). 
!
Regulation of PKC activity 
The regulation of PKC isozyme activity is achieved by a number of mechanisms including 
phosphorylation of Ser/Thr and tyrosine (Tyr) residues, site-specific proteolysis, ubiquitination, 
specific interactions with proteins, lipids and phorbol esters such as phorbol 12-myristate 13-
acetate (PMA), and all of these may modulate protein function or help target the different 
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isozymes to specific subcellular locations (Steinberg, 2008; Griner and Kazanietz, 2007; Parker 
and Murray-Rust, 2004; Newton, 1995).  
(I) Phosphorylation: 
(a) Serine/Threonine priming phosphorylations: Phosphorylation of Ser/Thr residues at 
the activation loop of the enzymatic active site is required for the activity of all PKC 
isozymes except for PKCδ, which has a glutamate residue that can act as a phospho-
mimetic active site phosphorylation in lieu of a phospho-Thr505 residue, but can be 
phosphorylated at the Thr residue nonetheless (Steinberg, 2008). Newly synthesized 
enzymes are targeted by the phosphoinositide-dependent kinase 1 (PDK1) protein kinase 
for phosphorylation at a conserved Ser/Thr residue within the active site, and this 
phosphorylation helps align the active site residues for optimal catalysis, generating an 
active enzyme (Newton, 1995; Griner and Kazanietz, 2007). The active enzyme then 
autophosphorylates at two residues located within the proline-rich “turn” motif and within 
the hydrophobic motif, both localized to the V5 region of the enzyme (Steinberg, 2008). 
These phosphorylations help stabilize the active form of the enzyme, and serve to keep it in 
a stable, closed conformation with the pseudosubstrate domain occupying the active site, 
after which the enzyme relocalizes to the cytosol (Freeley et al., 2011).  The enzyme is thus 
said to be “primed” for activation and remains in this inactive, but catalytically competent 
state, until activated by its specific cofactors when an appropriate signal is received 
(Newton, 1995). The active loop and C-terminus phosphorylations can also be mediated by 
other kinases as evidenced for PKCδ in which the PKCε isoform was found to 
phosphorylate the activation loop, and PKCζ and the mammalian target of rapamycin 
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(mTOR) were found to mediate phosphorylation of the C-terminal hydrophobic motif 
(Rybin et al., 2007; Parekh et al., 1999; Zeigler et al., 1999).  
(b) Tyrosine phosphorylations: Phosphorylation at a number of Tyr residues in PKCδ has 
been reported to increase its activity, alter its substrate specificity and even activate the 
enzyme independently of DAG under oxidative stress conditions (Steinberg, 2004). 
Tyrosine phosphorylations have also been reported to enhance the membrane affinity of a 
phosphorylated C2 domain in PKCθ and to modulate the enzymatic activities of aPKCs ζ 
and λ/Ɩ (Liu et al., 2000; White et al., 2002). 
(II) Proteolysis: Caspase-dependent cleavage of PKC isozymes δ, θ, ε and ζ has been reported as 
part of the apoptotic signaling cascade, and this cleavage frees the catalytic domain from the 
influence of the regulatory N-terminal domain. The nPKC isoforms δ, θ and ε remain 
catalytically active following caspase cleavage and can then mediate pro-apoptotic functions 
within the cell while the aPKC isozyme is presumed to be either inactivated after cleavage or 
thought to mediate kinase-independent functions in promoting apoptosis (Steinberg, 2008).  
(III) Subcellular localization: A number of targeting signals are found within the functional 
domains in PKC enzymes that direct the enzymes to specific organelles such as the nucleus, ER 
and the Golgi apparatus (Steinberg, 2008). Receptors for activated C kinase (RACK) proteins are 
also present in the cell where each RACK protein interacts with its specific kinase and helps 
localize the activated kinase in close proximity to its unique substrates (Parker and Murray-Rust, 
2004; Steinberg, 2008).  
!
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(IV) Ubiquitination: PKC isozymes are thought to be become ubiquitinated and destined for 
degradation following their activation. The identities of the E3 ligases mediating PKC 
ubiquitination remain elusive (Griner and Kazanietz, 2007). Recently, RINCK has been 
identified as a RING-containing E3 ubiquitin ligase that targets PKC isozymes from all three 
subfamilies for ubiquitination and proteasome-mediated degradation (Chen et al., 2007). RINCK 
was found to localize to the plasma membrane, to bind the C1A domain of PKC isozymes 
directly, and to regulate the basal levels of PKC enzymes in the cell, independently of their 
activation states.  
(V) Phosphatidylserine binding: Phosphatidylserine is bound by both the C1 and C2 domains of 
PKC enzymes and this binding is thought to increase the enzyme’s affinity for the plasma 
membrane and help stabilize its structure possibly by interfering with intramolecular C1-C2 
interactions (Steinberg, 2008).  
(VI) Phorbol esters: Phorbol esters such as PMA are DAG analogs that can bind the C1 domains 
of cPKCs and nPKCs with high affinity (Mellor and Parker, 1998). Unlike DAG, phorbol esters 
cannot be metabolized and thus result in the constitutive activation of DAG-responsive PKC 
isoforms, and this activation may result in downregulation of certain isozymes (Griner and 
Kazanietz, 2007; Mackay and Twelves, 2007). Phorbol esters have been reported to induce tumor 
formation in mouse models, but it is unknown if tumorigenesis is promoted by ester-mediated 
activation or ester-mediated downregulation of PKC enzymes (Mackay and Twelves, 2007; 
Griner and Kazanietz, 2007). 
!
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Physiological relevance of the PKC family of kinases 
Substrates of the PKC family enzymes are not well-defined, possibly owing to the highly 
conserved structural features amongst the isozymes, rendering the identification of isozyme-
specific substrates a difficult task. Nonetheless, knockout mouse models have been useful in 
identifying isozyme-specific roles. PKCα, δ, and η have been implicated as tumor suppressors, 
and disruptions in these enzymes have been shown to enhance tumorigenesis and/or increase 
resistance to apoptosis (Oster and Leitges, 2006; Humphries et al., 2006; Chida et al., 2003). 
Transgenic mice overexpressing PKCε in the skin were found to be sensitized to UV-induced 
carcinogenesis (Reddig et al., 2000). Both PKCθ and PKCɩ knockout mice have implicated these 
isozymes as regulators of insulin function (Kim et al., 2004; Farese et al., 2007). Finally, the 
knockout mouse model of PKCɣ isozyme shows cognitive defects, implicating this enzyme as 
essential in the central nervous system function (Abeliovich et al., 1993). Apart from the PKCɩ 
knockout mice, none of the PKC knockout mice are embryonic lethal and display subtle 
phenotypes (Farese et al., 2007). It is thus evident from the near-normal phenotypes of these 
mice that some level of functional redundancy exists between the different PKC isozymes 
(Griner and Kazanietz, 2007). Understanding how each of these enzymes mediates their 
isozyme-specific function is contingent upon elucidation of isozyme-specific substrates and the 
mechanisms governing these functions are presently unknown. Aberrant expression of these 
isozymes has been reported in a number of cancers, and anti-cancer drug trials that target PKC 
isozymes have been undertaken with little success (Griner and Kazanietz, 2007; Mackay and 
Twelves, 2007). The elucidation of isoform-specific roles and substrates, as well as their 
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regulation, will clarify the role that they play in tumorigenesis and provide basis for rational, 
isoform-specific anti-cancer drug design. 
!
THE PROTEIN KINASE C δ 
!
PKCδ is a 78 kilo-Dalton (kDa), pro-apoptotic member of the novel subfamily of PKC enzymes. 
When a ligand engages its cognate GPCR or RTK at the cell surface, activation of 
phospholipase C ensues which results in PI hydrolysis and generation of the DAG second 
messenger (Parker and Murray-Rust, 2004; Figure 3). DAG then recruits an inactive PKCδ to the 
membrane and triggers a conformational change that dislodges the pseudosubstrate motif from 
the active site, resulting in an active PKCδ enzyme (Newton, 1995; Figure 3).  
 PKCδ-mediated signaling is preferentially activated in response to DNA damage-induced 
apoptosis and participates in the intrinsic apoptosis pathway, however, its precise role in the 
apoptotic response is ill-defined although it is known to elicit loss of the mitochondrial 
membrane potential and result in cytochrome c release, both hallmarks of mitochondrial 
apoptosis (Brodie and Blumberg, 2003). Only a few PKCδ substrates have been identified to date 
which include the DNA-dependent Protein Kinase (DNA-PK), phosphorylation of which results 
in the dissociation of DNA-PK from DNA and blockage of DNA repair, and lamin B, where 
phosphorylation promotes lamin B degradation by Caspase-6 and aids in the disassembly of 
nuclear lamina in apoptosis (Bharti et al., 1998; Cross et al., 2000). Furthermore, PKCδ-
mediated phosphorylation of the induced myeloid leukemia cell differentiation protein Mcl-1 
may help target the latter for proteasome-mediated degradation while that on Ser46 of p53 
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protein commits p53 to apoptotic signaling through upregulated expression of the pro-apoptotic 
p53 target genes PUMA and NOXA (Sitailo et al., 2006; Yoshida et al., 2006; Li et al., 2005; 
Ichwan et al., 2006). PKCδ can also be proteolytically activated during apoptotic signaling by 
Caspase-3, which targets the hinge region of the enzyme and separates the C-terminal kinase 
domain from the N-terminal regulatory region, which results in the release of a constitutively 
active PKCδ enzyme (Emoto et al., 1995; Ghayur et al., 1996). Strikingly, a PKCδ-/- knockout 
mouse model and two patients with a homozygous, loss-of-function or deletion mutations in the 
PKCδ gene display signs of a lymphoproliferative disorder with B-cell hyperproliferation and 
splenomegaly, supporting an in vivo anti-proliferative, pro-apoptotic role for this kinase 
(Miyamoto et al., 2002; Kuehn et al., 2013; Salzer et al., 2013). Finally, the apoptotic response is 
severely impaired in cells isolated from both the knockout mice and from an aforementioned 
patient, and enforced expression of PKCδ in these cells helps restore their apoptotic competence, 
further highlighting the role of this isozyme as an important mediator of the apoptosis pathway in 
vivo (Humphries et al., 2006; Kuehn et al., 2013). 
 Regulation of PKCδ function takes on many forms. Like other PKC isozymes, the 
maturation of the enzyme involves priming Ser/Thr phosphorylations at the turn and 
hydrophobic motifs while a phosphorylation at the active loop is not required for enzyme 
maturation but does enhance catalytic activity (Stempka et al., 1997; Rybin et al., 2003; 
Steinberg, 2004). In addition, regulatory phosphorylation on multiple tyrosine sites have been 
identified and are thought to be mediated by Src family kinases and the Abl tyrosine kinase, and 
the in vivo function of these modifications may be to activate the enzyme independently of 
ligand-induced signaling, to serve as docking sites for other proteins or to increase Caspase-3-
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mediated cleavage of PKCδ (Blake et al., 1999; Yuan et al., 1998; Steinberg, 2004; Freeley et al., 
2011; Blass et al., 2002). It is believed that pools of differentially phosphorylated PKCδ protein 
may exist in the cell and that these phosphorylation codes may target different forms of PKCδ to 
different substrates and/or cellular locales (Steinberg, 2004). PKCδ can be shuttled to different 
cellular compartments in response to different stimuli; it can localize to the plasma membrane, 
upon DAG or phorbol ester binding to its C1 domain, to the nucleus, due to a nuclear 
localization signal housed in its C-terminus, and to the mitochondria (Brodie and Blumberg, 
2003; DeVries et al., 2002). Finally, DAG- and phorbol ester-mediated activation of PKCδ is 
known to induce its ubiquitination and subsequent 26S proteasome-mediated degradation, 
however, the identity of the E3 ubiquitin ligase mediating this step is still elusive (Lu et al., 
1998). Recently, RINCK has been identified as an E3 ubiquitin ligase that targets PKC isozymes 
from all three subfamilies for proteasomal degradation (Chen et al., 2007). However, RINCK 
does not participate in the PMA-induced degradation of PKC isozymes and the levels of the 
PKCδ isozyme were less sensitive to in vivo manipulations of RINCK protein expression, 
suggesting that RINCK primarily functions in the regulation of PKC enzymes’ basal cellular 
levels independently of their activation status (Chen et al., 2007).  
!
!
!
!
!
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THESIS RATIONALE 
!
In addition to p53, the Pirh2 E3 ubiquitin ligase targets a number of cellular substrates for 
ubiquitination including c-myc, p27/Kip1 and DNA polymerase η. A GST-pulldown assay using 
Pirh2 as bait had been previously employed to identify novel substrates and interacting protein 
partners of Pirh2, resulting in the identification of an N-terminal fragment of PKCδ as an 
interacting partner of Pirh2 (Tai, 2009). Activated PKCδ enzyme is known to be targeted for 
ubiquitination and subsequent proteasome-mediated protein degradation, however, the identity of 
the E3 ligase mediating this ubiquitination remains elusive (Lu et al., 1998). The objective of this 
research project was to validate a putative interaction between the Pirh2 and PKCδ proteins, to 
characterize this interaction and elucidate its significance. I tested the hypotheses that (i) PKCδ is 
a novel substrate of the Pirh2 E3 ubiquitin ligase; and that (ii) Pirh2 targets PKCδ protein for 
ubiquitination and subsequent protein degradation. Pirh2 may thus serve to functionally 
inactivate PKCδ and interfere with the PKCδ-mediated apoptotic response. 
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MATERIALS AND METHODS 
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Cell culture. Immortalized kidney fibroblast cell lines derived from wild-type (WT) and Pirh2 
null (Pirh2-/-) mice were previously generated by Elizabeth Tai in the Benchimol lab (Tai, 2009). 
Briefly, mouse kidney was harvested and separated into cells by passing through a 70 µm 
strainer. Cells were incubated in α-minimum essential medium (α-MEM) supplemented with 
10% fetal calf serum (FCS) at 37℃, 5% CO2 overnight, after which, cellular debris and media 
were removed and replaced with fresh α-MEM, 10% FCS. Adhered cells were washed with 
phosphate-buffered saline (PBS) and maintained in α-MEM, 10% FCS for one week, and were 
then immortalized using the 3T3 protocol (Xu, 2005). Immortalized wild-type and Pirh2-/- cells 
were maintained in α-MEM supplemented with 10% fetal bovine serum (FBS) at 37℃, 5% CO2. 
H1299 cells in which endogenous Pirh2 protein expression can be inducibly knocked down 
(H1299-Pirh2-KD) were provided by Drs. Xinbin Chen and Rasqallah Hakem (Jung et al., 
2010). Both parental H1299 and H1299-Pirh2-KD were maintained in RPMI-1640 medium 
supplemented with 10% FBS at 37℃, 5% CO2. The MCF-7 cell line was maintained in α-MEM 
supplemented with 10% FBS at 37℃, 5% CO2. MCF-7 cells stably transfected with Pirh2 
expression vectors encoding either the wild-type protein, the C164A and H169A mutants, both of 
which disrupt the RING domain of Pirh2 by mutating the Cys and His at positions 164 and 169, 
respectively, to Alanine (A; Ala), or the ΔRING Pirh2 mutant which lacks the RING domain 
motif, were all previously generated by Roger Leng in the Benchimol lab (Leng et al., 2003). 
Mouse organs. Mouse kidney, lung and liver from matched WT and Pirh2-/- mice were kind 
gifts from Dr. Rasqallah Hakem (Hakem et al., 2011). Organs were minced and lysed in 2X SDS 
Lysis Buffer (0.136 M Tris-HCl, pH 6.8, 4% SDS, 20% glycerol) and the lysates were aliquoted 
and frozen at -80℃. 
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Cell Lysis, SDS-PAGE and immunoblotting. Cells were washed once with PBS and lysed 
directly in 2X SDS Lysis Buffer on ice. Lysates were then heated at 99°C for 5 minutes, followed 
by centrifugation at 14000 x g for 10 minutes; to pellet cellular debris. Protein concentration was 
determined using the BCA Protein Assay (Pierce). A pre-determined amount of total protein was 
mixed with 0.04% bromophenol blue and 100 mM dithiothreitol (DTT), loaded onto a 12% 
polyacrylamide gel containing SDS, resolved by electrophoresis, and transferred onto 
polyvinylidene difluoride (PVDF) membranes.  
 The PVDF membrane was blocked using TBST (20 mM Tris-HCl, pH 7.5, 0.3 M NaCl, 
0.05% Tween-20) containing non-fat milk and/or bovine serum albumin (BSA). Primary and 
secondary antibodies were prepared in TBST containing non-fat milk and/or BSA and incubated 
with the membrane for pre-determined time periods. TBST was utilized for all intermediate 
washes of the membrane. 
 Enhanced chemiluminescence (ECL) (Amersham Biosciences) was used to detect 
proteins of interest on the PVDF membrane. Equal protein loading of each sample was 
confirmed by re-probing of membranes with β-actin antibody.  
Antibodies. The following antibodies and their respective dilutions were used for 
immunoblotting: rabbit anti-human PKCδ (C-20 (sc-937), Santa Cruz, 1:5000), rabbit anti-
human PKCδ (CS-#2058, Cell Signalling, 1:1000), rabbit anti-human Pirh2 (A300-357A, Bethyl 
Laboratories, 1:5000), GST-purified rabbit anti-mouse Pirh2 (serum, Benchimol lab, 1:5000), 
crude rabbit anti-mouse Pirh2 (serum, Benchimol lab, 1:10,000), mouse anti-human p53 (DO-1 
(sc-126), Santa Cruz, 1:1000), mouse anti-β-actin (A2228, Sigma Aldrich, 1:60,000), sheep anti-
mouse horse-radish peroxidase-(HRP-) conjugated antibody (515-035-003, Jackson 
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ImmunoResearch Inc., 1:10,000-1:50,000) and goat anti-rabbit HRP-conjugated antibody 
(111-035-003, Jackson ImmunoResearch Inc., 1:30,000).  
shRNA-mediated Pirh2 protein knockdown. Treatment of the H1299-Pirh2-KD cell line with 
tetracycline (Tet) induces shRNA-mediated knockdown of endogenous Pirh2 expression (Jung et 
al., 2010). Both parental H1299 and H1299-Pirh2-KD cells were treated with tetracycline for 72 
hour to completely knockdown endogenous Pirh2 expression. Following treatment with Tet for 
48 hours, cells were treated with PMA, a DAG analog that is known to activate PKCδ and induce 
its ubiquitination and subsequent degradation, for 24 hours (Lu et al., 1998). Cells were lysed in 
2X SDS Lysis Buffer and lysates were assayed by immunoblotting. 
Transient overexpression of Pirh2 protein. MCF-7 cells were transfected for 48 hours using 
Lipofectamine 2000 (Invitrogen), as per manufacturer instructions, with empty vector or with 
Pirh2 expression vectors encoding wild-type protein (5 or 10 µg, as indicated) or mutant Pirh2 
proteins with defective E3 ligase activity (C164A and H169A Pirh2 expression vectors, 5 µg; 
Leng et al., 2003). Cells were either left untreated or treated with PMA for an additional 24 hours 
prior to lysis in 2X SDS Lysis Buffer. Lysates were assayed by immunoblotting. 
Stable overexpression of wild-type, C164A, H169A and ΔRING Pirh2 proteins. Both 
parental MCF-7 cells and MCF-7 cells stably transfected with Pirh2 expression vectors C164A, 
H169A and ΔRING were treated with PMA for time periods ranging from 30 minutes to 48 
hours to induce activation and degradation of PKCδ protein. At the appropriate time point, cells 
were lysed in 2X SDS Lysis Buffer and lysates were assayed by immunoblotting.   
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Pirh2 interferes with steady state levels of PKCδ protein in immortalized kidney 
fibroblasts. The levels of PKCδ protein were assessed in extracts of immortalized kidney 
fibroblasts from wild-type (WT) and Pirh2 null (Pirh2-/-) mice under normal growth conditions. 
If Pirh2 is indeed the E3 ligase responsible for ubiquitin-mediated degradation of PKCδ, then the 
endogenous levels of PKCδ protein should be elevated in the Pirh2-/- cells. Indeed, expression of 
the full length PKCδ protein, seen as a band around 72 kDa, was elevated in the Pirh2-/- kidney 
cells compared with WT kidney cells (Figure 4). After the membranes were incubated with anti-
Pirh2 antibody, I confirmed that the Pirh2-/- cells lacked Pirh2 protein expression, and thus the 
differential levels of PKCδ protein expression were likely a result of the altered Pirh2 protein 
expression (Figure 4). β-actin was used as a protein loading control (Figure 4). 
 Since the kidney fibroblasts cell lines were immortalized, we wondered whether this 
increase in PKCδ levels might be an artifact of the immortalization procedure, and wanted to 
confirm the results in a more physiologically relevant setting. Thus, the same experiment was 
repeated using mouse organs from matched WT and Pirh2-/- mice. 
!!!!!!!!!!!!!!!
!37
!!!!!!
!
!
!
!
!
!
!
!
!
!
!
!
FIGURE 4: PIRH2 INTERFERES WITH THE STEADY STATE LEVELS OF PKCδ IN 
IMMORTALIZED KIDNEY FIBROBLASTS. Protein extracts from WT and Pirh2-/- 
immortalized kidney fibroblasts were resolved by SDS-PAGE and analyzed by immunoblotting 
with antibodies to PKCδ (sc-937) and Pirh2. β-actin was used as a protein loading control. Arrow 
indicates full-length PKCδ. 
!
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Pirh2 interferes with steady state levels of PKCδ in mouse kidney and lung tissues. PKCδ 
protein expression in mouse kidney, lung and liver organs from WT and Pirh2-/- mice was 
assessed by immunoblotting (Figure 5). In both the kidney and the lung, full-length PKCδ 
protein levels were elevated in the Pirh2-/- tissues compared with WT tissues, although the effect 
was more pronounced in the lung (Figure 5). An additional band at 34 kDa, unique to tissues 
derived from Pirh2-/- mice, was also observed, however, the identity of this band remains 
unclear, but may represent a fragmented PKCδ (Figure 5). The C-terminus catalytic domain, at 
40 kDa, is not expected to run at this level in the protein gel. Pirh2 protein was expressed in both 
WT kidney and lung, and absent in the matched Pirh2-/- organs (Figure 5). β-actin was used a 
protein loading control (Figure 5).  
 A unique banding pattern was observed in the Pirh2-/- liver and not in the WT tissue 
(Figure 5). Of note, higher expression was also observed of 34 kDa band in the Pirh2-/- liver 
compared to the WT tissue, and at 43 kDa, where the C-terminus catalytic fragment is expected 
to run, however, no such differential is observed at 72 kDa, where a band corresponding to full-
length PKCδ protein would be expected (Figure 5). However, both organs seemed to lack Pirh2 
protein expression, and thus, results from this organ were not considered. It seems likely that the 
observed band at 34 kDa in all Pirh2-/- organs may represent a non-specific interaction with the 
antibody. In summary, these findings show that Pirh2 protein expression interferes with steady 
state protein levels of PKCδ both in vitro and in vivo in select tissues.   
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The effect of shRNA-mediated knockdown of Pirh2 expression on protein levels of 
endogenous and activated PKCδ. To further confirm the effects of Pirh2 protein abrogation on 
levels of PKCδ protein, we next used a cell system in which Pirh2 protein expression can be 
inducibly downregulated. H1299-Pirh2-KD cells were successfully used by Jung et al. (2010) to 
identify DNA polymerase η as a target for Pirh2 protein. We wanted to investigate the effects of 
Pirh2 protein abrogation on the steady state levels of PKCδ in cells with endogenous expression 
of both proteins.  
 H1299-Pirh2-KD cells were treated with and without tetracycline as described in 
Materials and Methods. To control for tetracycline-mediated effects on protein expression, we 
included the parental H1299 cell line to act as a baseline control as well as a positive control for 
PMA-mediated PKCδ degradation. To test whether prior activation of PKCδ was necessary for 
its association with Pirh2 and subsequent degradation, I treated cells with PMA, a DAG analog 
and PKCδ activator that induces its ubiquitination and subsequent degradation (Lu et al., 1998). 
In the parental H1299 cell line, treatment with tetracycline should not interfere with levels of 
either Pirh2 or PKCδ proteins, and indeed, it did not (Figure 6, middle panel; lanes 1 and 2). 
Furthermore, treatment of the parental H1299 cell line with PMA should induce downregulation 
of full-length PKCδ protein, reflected on an immunoblot as a decrease in its protein levels, which 
was observed in Figure 6 (Upper panel; compare lanes 3 and 4 with lanes 1 and 2). Treatment of 
the H1299-Pirh2-KD with Tet should induce complete downregulation of Pirh2 protein levels, 
however, only a mild decrease in Pirh2 protein expression was observed (Jung et al., 2010; 
Figure 6, middle panel; compare lanes 5 and 6). This mild decrease was not accompanied by an 
increase in endogenous PKCδ protein levels, contrary to what we had seen in both the 
!41
immortalized kidney fibroblast cell lines and the mouse organs where Pirh2 protein levels were 
abrogated completely (Figures 4 and 5).  
 If Pirh2 is the E3 ligase mediating PMA-induced ubiquitination of PKCδ, PMA treatment 
of cells lacking Pirh2 protein expression should not result in PKCδ degradation. However, 
treatment with PMA resulted in a decrease in PKCδ protein levels, whether the cells were pre-
treated with Tet or not (Figure 6, upper panel; compare lanes 7 and 8 with lanes 5 and 6). 
Interestingly, treatment of cells with both PMA and Tet led to a mild increase in Pirh2 protein 
expression, and thus interfered with Tet-induced Pirh2 protein knockdown (Figure 6, middle 
panel; compare lanes 6 and 8). Since Pirh2 protein expression was not successfully 
downregulated using the H1299-Pirh2-KD system, this cell line was not useful in identifying 
whether Pirh2 is the E3 ubiquitin ligase mediating ubiquitination of PKCδ in response to PMA 
treatment.  
 A band observed just below 34 kDa that disappeared with Tet treatment in H1299-Pirh2-
KD cells was probably an artifact of Tet treatment, as it was not observed in the parental cell line 
(Figure 6). β-actin served as a protein loading control (Figure 6). 
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FIGURE 6: THE EFFECT OF shRNA-MEDIATED KNOCKDOWN OF PIRH2 
PROTEIN EXPRESSION ON STEADY STATE AND ACTIVATED PKCδ PROTEIN 
LEVELS. Parental H1299 and H1299-Pirh2-KD cells were treated with Tet for 72 hours, to 
induce knockdown of Pirh2, and with PMA for 24 hours, to activate PKCδ and stimulate its 
ubiquitination. Cells were lysed, their lysates resolved by SDS-PAGE, and assayed by 
immunoblotting with antibodies to PKCδ (sc-937) and Pirh2. β-actin was used as a protein 
loading control. Arrow indicates full-length PKCδ. 
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Transient overexpression of Pirh2 protein does not interfere with endogenous PKCδ 
protein levels. In addition to shRNA-mediated knockdown of Pirh2 protein levels, 
overexpression of Pirh2 protein can also be used to assess the effect of Pirh2 protein on the 
steady state levels of PKCδ protein, and was successfully used in identifying p53 as a bonafide 
substrate for Pirh2 (Leng et al., 2003). Thus, transient overexpression of Pirh2 protein was next 
attempted to investigate the effects of enforced Pirh2 protein expression on PKCδ protein levels.  
 MCF-7 cells were transfected with empty vector or with different amounts of Pirh2 
expression vectors encoding either the wild-type protein or the C164A and H169A mutants. Both 
these mutants disrupt the RING domain of Pirh2, by mutating the Cys and His at positions 164 
and 169, respectively, to Ala and thus express an inactive Pirh2 protein with no E3 ligase activity 
(Leng et al., 2003). The protein levels of PKCδ, p53, and Pirh2 were assessed by 
immunoblotting (Figure 7). β-actin served as a loading control (Figure 7). 
 Ectopic expression of Pirh2 protein was assessed by comparing endogenous protein 
levels in cells transfected with empty vector with those in which Pirh2 protein expression was 
enforced using expression constructs (Figure 7). Enforced expression of wild-type Pirh2 protein 
did not result in a decrease in protein levels of PKCδ, contrary to what was expected (Figure 7). 
Steady state levels of PKCδ protein were increased in cells with enforced expression of Pirh2 
mutants, compared with both empty vector and wild-type Pirh2, which indicated that the E3 
ligase activity of Pirh2 may be necessary for its ability to interfere with PKCδ protein levels 
(Figure 7). Interestingly, p53 protein levels, expected to decrease in the presence of 
overexpressed wild-type Pirh2, were also unaffected in spite of the fact that Pirh2 is a validated 
!44
E3 ligase for p53 (Figure 7). Successful ectopic expression of Pirh2 protein was verified for both 
the wild-type protein and the H169A mutant (Figure 7). 
 I next decided to test whether prior activation of PKCδ was necessary for its association 
with Pirh2 and thus treated cells with PMA following their transfection with expression 
plasmids. Since the C164A construct was not efficiently expressed, it was not included in 
subsequent experiments.  
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FIGURE 7: EFFECT OF TRANSIENT OVEREXPRESSION OF WILD-TYPE AND 
MUTANT PIRH2 PROTEIN ON STEADY STATE PKCδ PROTEIN LEVELS IN MCF-7 
CELLS. Cells were transfected with empty vector or with Pirh2 expression plasmids encoding 
either the wild-type protein (Pirh2) or mutants which lack the E3 ligase activity (C164A and 
H169A). Levels of endogenous PKCδ (CS-#2058) and p53 proteins and of ectopically expressed 
Pirh2 proteins were assayed by immunoblotting with their respective antibodies. β-actin was 
used as a protein loading control. 
!
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PMA downregulates PKCδ protein levels in cells with enforced expression of both wild-type 
and mutant Pirh2 protein. MCF-7 cells were transfected with empty vector or with different 
amounts of Pirh2 expression vectors encoding either the wild-type protein or the H169A mutant. 
After transfection, cells were treated with PMA for 24 h. The protein levels of PKCδ, p53, and 
Pirh2 were assessed by immunoblotting (Figure 8).  
 Ectopic expression of Pirh2 protein was assessed as aforementioned. Ectopic expression 
of Pirh2 protein did not result in a decrease in steady-state protein levels of PKCδ (Figure 8). 
Steady state levels of PKCδ protein were not altered in cells with enforced expression of the 
H169A Pirh2 mutant (Figure 8). PMA treatment for 24 hours induced downregulation of PKCδ 
protein regardless of whether Pirh2 protein was overexpressed (Figure 8). p53 protein levels, 
expected to decrease in the presence of overexpressed wild-type Pirh2, were only mildly 
decreased in the presence of overexpressed Pirh2 (5 µg) but were unaffected in other lanes 
(Figure 8). PMA treatment induced downregulation of p53 protein as well, but this was not 
further investigated (Figure 8). Ectopic expression of Pirh2 protein was not observed in some 
samples (Figure 8). β-actin served as a loading control (Figure 8). 
 Based on these data, transient overexpression of Pirh2 in MCF7 cells was not further 
attempted. Enforced expression of the protein of interest was only seen in some of the cells 
transfected with expression constructs. Widespread toxicity to the cells, resulting in cell death, 
was observed and thus yielded a low number of surviving cells for analysis. This toxicity may 
also impair analysis as it may interfere with p53 protein activation, and thus with Pirh2 protein 
levels. From this point forward, I decided to use stable MCF-7 cells that stably express either 
wild-type or mutant Pirh2 protein. 
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The effect of stable overexpression of wild-type Pirh2 protein and its mutants on PKCδ 
protein levels. MCF-7 cells stably transfected with Pirh2 expression vectors encoding either the 
wild-type protein or the C164A, H169A and ΔRING mutants were used. Parental MCF-7 cells 
served as a control. Cells were treated with PMA for 30 min (Figure 9) and over a time course of 
3 to 48 h (Figure 10), to induce the activation and degradation of PKCδ. The protein levels of 
PKCδ, p53, and Pirh2 were assessed by immunoblotting (Figures 9 and 10).  
 Levels of endogenous PKCδ protein were unaffected in cells with enforced expression of 
wild-type Pirh2, compared to the parental line, but were elevated in cells with enforced 
expression of the Pirh2 mutants (Figure 9). Treatment of the cells with PMA for 30 min did not 
induce downregulation of PKCδ protein levels (Figure 9). Levels of p53 protein were only 
slightly increased in cells with enforced expression of the C164A and H169A mutants, but this 
was barely visible and deemed not significant (Figure 9). Enforced expression of Pirh2 protein 
was assessed by comparing Pirh2 protein expression in cells stably overexpressing Pirh2 protein 
with endogenous Pirh2 protein expression in parental MCF-7 cells (Figures 9 and 10). Enforced 
expression of Pirh2 protein was detected for the wild-type and the ΔRING proteins (Figure 9). 
Pirh2 protein levels of the C164A mutant were comparable to those seen in the parental cell line 
while the H169A mutant was not consistently expressed (Figure 9). β-actin served as a loading 
control (Figure 9).  
 PMA treatment of the parental MCF-7 cells, with no exogenous expression of Pirh2 
protein, did not downregulate protein levels of PKCδ (Figure 10). Strikingly, PKCδ protein 
levels seemed to increase with PMA treatment in those cells, which was unexpected (Figure 10). 
PMA treatment of parental cells for 48 hours, however, resulted in complete downregulation of 
!49
PKCδ (Figure 10). Levels of endogenous PKCδ were increased in cells with enforced expression 
of wild-type Pirh2 protein when compared with the parental MCF-7 cell line (Figure 10). PMA 
treatment of cells with enforced expression of wild-type Pirh2 resulted in a minor decrease in 
PKCδ levels by the 6 h timepoint, however, PKCδ protein was still detected 48 h after PMA 
treatment (Figure 10). Levels of PKCδ protein were stable up to 6 h following PMA treatment in 
cells with enforced expression of the Pirh2 protein mutants, however, PMA still induced 
complete degradation of PKCδ protein by 48 h in these cells (Figure 10). These results all 
indicate that Pirh2 is not the E3 ligase responsible for steady state or PMA-induced 
downregulation of PKCδ. p53 protein levels in cells with stable expression of Pirh2 or its 
mutants were inconsistent with prior published data, with an increase in p53 protein levels 
observed in some cells with enforced expression of wild-type Pirh2 (Figure 10). Finally, Pirh2 
protein was not consistently expressed while β-actin served as a loading control (Figure 10). 
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DISCUSSION 
!
The results of this study were suggestive, but not conclusive, of an intracellular regulatory 
mechanism involving Pirh2 and PKCδ. Following the identification of a novel interaction 
between Pirh2 and PKCδ, it was exciting to observe that levels of PKCδ protein were higher in 
immortalized kidney fibroblasts derived from Pirh2-/- mice as compared to those derived from 
WT littermates (Fig. 4). Further confirmation of the elevated levels of PKCδ protein in select 
Pirh2-/- tissues led us to speculate that PKCδ was a bonafide substrate of the Pirh2 E3 ligase, as 
similar results were observed for other, validated targets like p53 and c-myc (Fig. 5). We next 
investigated if the in vitro manipulation of cellular Pirh2 protein levels would affect those of its 
presumed substrate, however, those efforts were not successful (Figs. 6-10). The tetracycline-
induced shRNA-mediated Pirh2 knockdown system had been successfully used in elucidating 
the effects of Pirh2 protein abrogation on levels of DNA polymerase η and the c-myc proto-
oncogene (Jung et al., 2010; Hakem et al., 2011). The fact that Pirh2 protein expression was not 
consistently downregulated upon tetracycline treatment of those cells was, as such, unexpected 
and did not further our understanding of the regulation of PKCδ levels by Pirh2 (Fig. 6).  
 To circumvent this problem, we decided to assess the effect of enforced Pirh2 protein 
expression on levels of the PKCδ enzyme, arguing that if PKCδ was a bonafide substrate for 
Pirh2-mediated polyubiquitination and subsequent proteasome-mediated degradation, PKCδ 
levels would decrease as Pirh2 protein expression increases (Figs. 7 and 8). Furthermore, we also 
used expression constructs that encode an inactive Pirh2 enzyme with a destabilized RING 
domain, to assess whether the E3 ubiquitin ligase function was required for regulation of PKCδ 
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protein levels (Figs. 7 and 8). In contrast with previous data published using the same constructs, 
enforced Pirh2 expression was only observed in some of the transfected cellular lysates, and this 
increased expression did not consistently interfere with steady-state levels of either its presumed 
substrate, PKCδ, or its bonafide substrate p53 (Figs. 7 and 8; Leng et al., 2003). Transient 
transfection of Pirh2 expression constructs led to widespread cellular toxicity and this may have 
acted as a negative selective pressure such that, only cells with poor or no uptake of the 
expression construct were viable and could be used for protein sample collection. In light of this 
toxicity, MCF-7 cells with stable overexpression of Pirh2 protein or its inactive protein mutants 
were used to confirm if enforced Pirh2 protein expression interfered with levels of PKCδ protein 
(Figs. 9 and 10). Enforced Pirh2 protein expression was not observed in all samples, perhaps as 
result of the cells losing the expression constructs over time (Leng et al., 2003; Figs. 9 and 10). 
Furthermore, no clear conclusion could be made regarding the mechanism of Pirh2-mediated 
regulation of either PKCδ or p53 levels, in contrast with prior experiments using the same cells 
(Leng et al., 2003; Figs. 9 and 10). It was particularly surprising to observe that the steady state 
levels of p53 protein were not downregulated by enforced expression of the Pirh2 protein as had 
been previously published (Leng et al., 2003). This may be explained by the fact that subsequent 
research revealed that Pirh2 may preferentially target active p53 for degradation and that its role 
in the regulation of steady state levels of p53 may be a minor one (Leng et al., 2003; Hakem et 
al., 2011; Sheng et al., 2008).  
 Since it is known that the phorbol ester PMA both activates PKCδ and targets it for 
ubiquitination and proteasome-mediated degradation, in what has been dubbed a “suicide 
model”, we stimulated cells with and without PMA to ensure that PKCδ can be effectively 
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downregulated in our cellular systems and to assess if the Pirh2 E3 ubiquitin ligase was involved 
in PMA-mediated PKCδ protein degradation (Lu et al., 1998). It was thought that the absence of 
Pirh2 protein expression would interfere with or, perhaps altogether impair, PMA-mediated 
downregulation of PKCδ protein, while the presence of overexpressed Pirh2 protein would 
perhaps enhance PMA-mediated PKCδ protein degradation. Surprisingly, PMA-mediated 
downregulation of PKCδ occurred both in the presence of elevated wild-type Pirh2 protein 
protein expression and in the presence of mutant Pirh2, further indicating that Pirh2 was not 
involved in PMA-mediated PKCδ protein degradation (Figs. 8, 9 and 10). In particular instances, 
PMA seemed to interfere with both Pirh2 and p53 protein levels and it is not immediately clear 
why this was observed (Figs. 6, 8, 9 and 10). In light of these data, it is my view that the Pirh2 
E3 ubiquitin ligase is not involved in PMA-mediated downregulation of PKCδ protein levels and 
that PKCδ is not a bonafide substrate for Pirh2-mediated polyubiquitination and subsequent 
proteasomal degradation. If a physical interaction between Pirh2 and PKCδ is confirmed, this 
interaction may induce Pirh2-mediated mono- or multi-ubiquitination of PKCδ, much like Pirh2-
mediated regulation of DNA polymerase η, which may influence PKCδ function, subcellular 
localization or protein interaction (Jung et al., 2011). Alternatively, PKCδ may target Pirh2 for 
phosphorylation to influence Pirh2 function or stability, much like CamKII and Cdk9 (Duan et 
al., 2007; Bagashev et al., 2013). 
 Future experiments to investigate this putative interaction should include another 
validated Pirh2 substrate, such as p27/Kip1, as a positive control in immunoblots, both to help 
clarify if the enforced expression is successful and to provide a baseline for Pirh2-mediated 
protein degradation (Hattori et al., 2007). Alternatively, treatment of cells with a DNA damaging 
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agent such as ɣ- or ultraviolet (UV)-irradiation or etoposide may help stimulate both p53-
mediated transactivation of the PIRH2 gene and the interaction between Pirh2 and any proteins it 
may bind, perhaps including PKCδ which is known to be activated downstream of such signals 
(Leng et al., 2003; Brodie and Blumberg, 2003). If the interaction is enhanced, it would help 
elucidate the mechanisms of Pirh2-mediated regulation of PKCδ protein levels and illuminate the 
physiological contexts under which such an interaction occurs to understand its significance. 
Under such circumstances, the Pirh2-p53 interaction would also be stimulated and a more 
accurate p53 positive control signal would be expected (Hakem et al., 2011). In fact, such DNA 
damaging agents have been used during the course of validating c-myc, DNA polymerase η and 
Chk2 to assess the effect of Pirh2 protein expression on protein levels of its substrates (Hakem et 
al., 2011; Jung et al., 2011; Bohgaki et al. 2013). Additionally, it is clear that some optimization 
of the cellular models used in this study is warranted, seeing as the results I have obtained were 
not consistent with prior published data, and thus the correct dosages of tetracycline, PMA and 
the Pirh2 expression constructs must be determined (Leng et al., 2003; Jung et al., 2010). If these 
experiments reveal an inverse relationship between Pirh2 protein expression and PKCδ protein 
levels, immunoprecipitation should be attempted using both endogenous and overexpressed 
proteins to see if the two proteins interact and form a complex in vivo. Thereafter, a series of 
GST-tagged full length and truncated Pirh2 and PKCδ proteins should be generated and used as 
bait in pulldown experiments to delineate the binding parameters for the putative PKCδ-Pirh2 
interaction. Functional studies such as in vitro and in vivo ubiquitination assays would clarify if 
the E3 ubiquitin ligase function is involved in Pirh2-mediated regulation of PKCδ protein levels. 
To assess if Pirh2 interferes with the pro-apoptotic function of PKCδ, cells with endogenous, 
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enforced and no Pirh2 protein expression should be treated with apoptosis-inducing agents such 
as etoposide and adriamycin and levels of induced apoptosis should be determined using flow 
cytometry and Annexin V staining or immunoblotting for cleaved caspases (Brodie and 
Blumberg, 2003). Finally, the previous GST-pulldown assay using GST-tagged Pirh2 protein as 
bait to probe protein lysates was limited in the identification of novel Pirh2 protein partners. It 
required the resolution of eluates from both GST-probed and GST-Pirh2-probed pulldown 
experiments on a polyacrylamide gel, and only the bands that were visibly exclusive to the GST-
Pirh2 eluate were excised and sent for identification by mass spectrometry (Tai, 2009). This may 
exclude proteins that were not as strongly bound by Pirh2, which may not be visible on a 
Coomassie-stained gel, and would not positively identify if GST-Pirh2 was found in the eluate, 
since this band was excluded from analysis based on molecular weight estimation. It is thus 
recommended that, after a number of stringent washes to eliminate non-specific interactions, 
mass spectrometry analysis should be performed on entire protein eluates from GST-pulldown 
experiments to identify both major and minor protein interacting partners of Pirh2. This would 
additionally help evaluate if the pulldown experiment was successful since validated Pirh2 
substrates like p27/Kip1, p53 and c-myc would be expected in GST-Pirh2-probed samples in 
addition to the GST-tagged Pirh2 bait itself and would reveal a number of new interacting 
partners that can then be further validated. 
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FUTURE DIRECTIONS 
!
In the ten years that have elapsed since the characterization of the PIRH2 gene product as a p53-
induced E3 ubiquitin ligase, much has been learnt about its in vivo function and the significance 
of having yet another E3 ubiquitin ligase targeting p53 in a negative feedback loop. A number of 
additional Pirh2 substrates have been identified including the p27/Kip1 cell cycle inhibitor, c-
myc and Chk2 (Hattori et al., 2007; Hakem et al., 2011; Bohgaki et al., 2013). Furthermore, 
levels of Pirh2 protein have been reported to be overexpressed in lung and prostate cancers and 
also, surprisingly, downregulated in ovarian and breast cancers, and as such, this protein may 
function in both oncogenic and tumor-suppressive mechanisms in a tissue-specific manner (Duan 
et al., 2004; Logan et al., 2006; Hakem et al., 2011). Future investigations into Pirh2 protein 
function, its substrates and interacting partners, and its regulation will help illuminate its precise 
in vivo role and hopefully reveal the mechanisms by which it may drive tumorigenesis. To this 
end, we propose a number of questions that need to be addressed to help clarify the physiological 
function of the Pirh2 E3 ubiquitin ligase.  
!
I. Does Pirh2 engage and complex with additional cellular partners in vivo? 
Pirh2 has been found to ubiquitinate a number of substrates since it was characterized as a p53-
specific E3 ubiquitin ligase including the c-myc proto-oncogene, DNA polymerase η, and p27/
Kip1 cell cycle inhibitor (Hakem et al., 2011; Jung et al., 2011; Hattori et al., 2007). 
Additionally, Pirh2 is known to associate with other cellular proteins such as Tip60, the latter of 
which stabilizes Pirh2 protein, and the scaffolding protein Axin, with which it associates in an 
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E3-independent manner, highlighting that we have just scratched the surface on Pirh2 protein 
partners (Logan et al., 2004; Li et al., 2009). Finally, Pirh2 is known to mediate both mono- and 
poly-ubiquitination of distinct substrates and it is, as-of-yet, unclear how and under what 
contexts Pirh2 modulates its E3 ubiquitin ligase activity such that it results in a different 
ubiquitin outcome on different substrates (Jung et al., 2011; Leng et al., 2003; Bohgaki et al., 
2013; Hakem et al., 2011). It is possible that Pirh2 may interact with cofactors and elongation 
partners, so called “E4s”, to mediate polyubiquitination or that it may recruit proteins with 
ubiquitin binding domains to cap the ubiquitin chain after a certain number of ubiquitin 
monomers have been attached (Koegl et al., 1999; Flick et al., 2006; Fang and Weissman, 2004). 
As aforementioned, GST-pulldown experiments using Pirh2 protein as bait can be used to probe 
whole cell lysates for interacting proteins and the eluates from such experiments should be 
analyzed by mass spectrometry to generate a number of putative protein targets and cofactors for 
further validation. The physiological contexts behind Pirh2-target protein engagement will be 
clarified as the number of its identified interacting partners increases, and this will shed light on 
both the in vivo role of Pirh2 protein and its role in pathophysiological conditions.  
!
II. What factors regulate Pirh2 protein stability and function in vivo? 
Pirh2 is known to be phosphorylated at four distinct residues by the two protein kinases CamKII 
and Cdk9, however, cellular signals that direct these post-translational modifications remain 
elusive (Duan et al., 2007; Bagashev et al., 2013). Furthermore, it is known that Pirh2 can 
autoubiquitinate and thus downregulate its own protein levels and that polyubiquitination of 
Pirh2 may be stimulated by its phosphorylation, while association of Pirh2 with Tip60 sequesters 
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Pirh2 protein and stabilizes it (Leng et al., 2003; Sheng et al., 2008; Duan et al., 2007; Bagashev 
et al., 2013; Logan et al., 2004). Pirh2 has a number of Ser/Thr residues interspersed within its 
primary structure and it is conceivable that a number of different Ser/Thr sites could be 
phosphorylated in vivo, by different kinases, to modulate its E3 ubiquitin ligase activity, alter its 
subcellular localization and protein interactions, or regulate its stability, in response to myriad 
cellular stimuli. In fact, the putative PKCδ-Pirh2 interaction that has been the subject of my 
thesis may result in PKCδ-mediated phosphorylation of the Pirh2 protein, as opposed to the 
presumed Pirh2-mediated ubiquitination of PKCδ. Intriguingly, an amino acid sequence that 
conforms to all but one residue of a PKCδ phosphorylation motif lies at the extreme C-terminus 
of Pirh2 protein, and it is interesting to speculate that PKCδ-mediated phosphorylation of this 
site may interfere with the Pirh2-p53 interaction, which is known to rely on the Pirh2 C-terminal 
domain to contact p53 (Steinberg, 2004; Sheng et al., 2008). Mutational analyses of these Ser/
Thr residues to Ala and Asp may reveal the functional role of such phosphorylations, while 
bioinformatic studies of surrounding residues can clarify if these sites represent consensus 
phosphorylation motifs for particular kinases. Furthermore, other post-translational modifications 
such as neddylation and sumoylation may regulate Pirh2 protein function and stability and these 
possibilities remain unexplored (Duda et al., 2008; Buschmann et al., 2000).  
!
III. What is the intracellular role of Pirh2 protein and what cellular pathways does it 
regulate? 
Pirh2 protein function is not required for development and Pirh2-/- mice develop normally and 
are fertile (Hakem et al., 2011). However, the precise physiological role of Pirh2 protein remains 
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obscure. Insight from recent work indicates that this protein may function as a master regulator 
of the DNA damage response. Pirh2 is known to preferentially target active p53 protein for 
degradation and to interfere with p53-mediated transactivation and cell-cycle arrest (Leng et al., 
2003; Hakem et al., 2011). Pirh2 has been also shown to target the DNA polymerase η for 
ubiquitin-independent, 20S proteasome-mediated degradation, however, it was subsequently 
found that Pirh2 monoubiquitinated the polymerase and interfered with polymerase η-mediated 
DNA repair (Jung et al., 2010; Jung et al., 2011). In another interesting example, Pirh2 
polyubiquitinates and downregulates the DNA damage response protein Chk2 following its 
dephosphorylation, which serves to shut off the DNA damage response (Bohgaki et al., 2013). 
Unlike activation of the Mdm2 and p21WAF1 genes, both of which are maximally induced at 8 h, 
p53-induced transactivation of the PIRH2 gene reaches a maximum 16 h after p53 is first 
activated in the DP16.1/p53ts cell line (Leng et al., 2003). This may indicate that: (a) p53 relies 
on those early genes in driving both cell cycle arrest and regulation of intracellular p53 levels 
following activation of p53 by DNA damage stress insults, and (b) Pirh2 may then be maximally 
induced once the DNA repair process is complete to downregulate the protein levels of the key 
mediators of the DNA damage response: activated p53 protein, DNA polymerase η and Chk2. 
Thereafter, Pirh2 may result in the ubiquitin-dependent degradation of the p27/Kip1 cell cycle 
inhibitor such that re-entry into the cell cycle is stimulated (Hattori et al., 2007). Figure 11 
illustrates a proposed model of intracellular Pirh2 protein function. 
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 Notably, Pirh2 has also been shown to interfere with p53-mediated apoptosis (Leng et al., 
2003; Hakem et al., 2011; Li et al., 2009). Pirh2 can function, independently of its E3 ligase 
activity, as a competitive inhibitor to block the formation of a pro-apoptotic complex between 
p53, the homeodomain-interacting protein kinase 2 (HIPK2) and Axin, a scaffold protein (Li et 
al., 2009). In unstressed or under sublethal levels of DNA damage, Pirh2 outcompetes the 
HIPK2-p53 complex from binding to Axin. However, once lethal doses of DNA damage are 
sensed, recruitment of the Tip60 protein to the Pirh2-Axin complex replaces Pirh2 on Axin and 
the scaffolding complex is then ready to bind HIPK2-p53, and mediate phosphorylation of p53 
on Ser46, which is thought to prime p53 for apoptosis (D’Orazi et al., 2002; Li et al., 2009; Li et 
al., 2005; Ichwan et al., 2006). Strikingly, Tip60 is also known to bind Pirh2 directly and alter its 
subcellular location, thus the recruitment of Tip60 to the Pirh2-Axin complex may serve two 
purposes: (i) to outcompete Pirh2 for binding to Axin and form a multi-protein complex with 
Axin and HIPK2-p53 and (ii) to bind and sequester Pirh2 away from the complex such that it can 
no longer compete for binding (Logan et al., 2004). Interestingly, Mdm2 is also thought to 
regulate levels of Ser46-phosphorylated p53 in response to non-lethal DNA damage levels by 
selectively targeting the HIPK2 kinase for ubiquitination and subsequent degradation (Rinaldo et 
al., 2007). Together, these data present a compelling model for why p53 may induce Pirh2 
protein expression: sublethal DNA damage insults activate p53, which results in cell cycle arrest. 
The expression from the PIRH2 gene is maximally induced 16 h after p53 activation, to allow 
time for DNA damage repair which, after Pirh2 protein is expressed, is then terminated by Pirh2-
mediated degradation of DNA damage repair effectors (Figure 11). At the same time, Pirh2 
competitively inhibits the formation of a multi-protein, pro-apoptotic complex and results in the 
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downregulation of the p27/Kip1 cell cycle inhibitor to re-stimulate the cell cycle, meanwhile 
Mdm2 targets HIPK2 for degradation and as such, apoptotic signaling is not stimulated (Figure 
11). p53 thus upregulates Pirh2 to regulate its own function such that p53-mediated cell cycle 
arrest and DNA repair is favored and apoptosis is suppressed. p53 also skilfully controls the 
levels of other DNA damage mediators to terminate DNA repair when needed. Once the cell 
encounters deadly stress, Tip60 tips the balance towards apoptotic signaling, and Pirh2 is 
outcompeted and sequestered. It is intriguing to speculate that lethal cellular insults may promote 
phosphorylation of Pirh2 to destabilize the protein such that the cell is primed for pro-apoptotic 
signaling. Figure 12 illustrates a proposed model for functionally inactivating Pirh2 under lethal 
stress conditions. 
 Finally, it is also notable that PKCδ itself has been shown to phosphorylate p53 on Ser46 
(Yoshida et al., 2006). Thus, Pirh2, if proven to target PKCδ for ubiquitination and subsequent 
degradation, may once again function to block the phosphorylation of the Ser46 residue and 
interfere with pro-apoptotic signaling by p53, under moderate cellular stress conditions (Figure 
12). Alternatively, lethal stress may activate PKCδ, which, in a two-pronged approach, 
phosphorylates both p53, on Ser46, and Pirh2, and perhaps at the C-terminus, to activate the 
former and presumably destabilize the latter (Duan et al., 2007; Bagashev et al., 2013; Figure 
12). The phosphorylation of Pirh2 at the C-terminus may also interfere with the Pirh2-p53 
interaction, as aforementioned, to functionally inactivate Pirh2 if its stability is not affected 
(Sheng et al., 2008). Thus, PKCδ may be activated separately or in conjunction with the HIPK2-
Tip60-Axin complex to stimulate pro-apoptotic signaling by p53.  
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